MENU

Can Profound Medical (PROF) Stock Reach $11?

a developer and manufacturee of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology

A.I.Advisor
published price charts
A.I.Advisor
Nov 12, 2026

Can Profound Medical (PROF) Stock Reach $11?

Profound Medical Corp. (PROF) is a Canadian commercial-stage medical device company best known for its TULSA-PRO system, an MRI-guided, incision-free ultrasound platform used to ablate prostate tissue. The stock has rebounded sharply off its 52-week low, and investors are now asking whether it can climb to roughly $11, a level that sits near the center of current Wall Street coverage.

Key Takeaways

  • The central target examined here is $11, the arithmetic mean of three verifiable current analyst price targets.
  • The reviewed analyst targets span a tight range of $10 to $12, with the stock trading near $7.44 at the time of writing.
  • Reaching $11 would require a gain of roughly 48% from the latest price.
  • Support comes from a strong Buy consensus, expanding commercial adoption of TULSA-PRO, and the stock's position above key moving averages.
  • Key risks include persistent net losses, competition in prostate treatment, and potential valuation compression after a sharp recent rally.
  • For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore these additional pages for deeper coverage and data.
  • Explore Trending AI Robots to see how AI-driven tools are monitoring stocks like PROF in real time.

Analyst Price Targets and Consensus View

PROF is not yet profitable, so analyst coverage is relatively thin, and only a handful of firms maintain current U.S.-dollar price targets. Reviewing the most recent verifiable targets, three firms stand out: Stifel Nicolaus (analyst Rick Wise) holds a $10 target, Raymond James (Michael Freeman) holds an $11 target, and Lake Street (Ben Haynor) holds a $12 target. The arithmetic mean of these three is $11.00, which serves as the central target throughout this article, with a range of $10 to $12.

The consensus rating across these firms is a unanimous Buy, with no Hold or Sell ratings among current coverage. That unanimity is notable for a small-cap medical device name, though it also reflects the limited number of analysts involved. Earlier coverage was more aggressive — Leede Financial's Douglas Loe carried a $15.25 target in 2025 — but that figure is now considered stale and is excluded. The narrow $10-to-$12 band indicates analysts broadly agree on the company's direction even as they differ modestly on near-term valuation.

Current Market Position and Path Toward the Target

The stock traded near $7.44 at the latest close, toward the upper end of a 52-week range of $4.80 to $8.95. Reaching $11 would require an advance of approximately 48% from that level — a substantial move that implies not just continued execution but an expansion of investor confidence in the company's commercial ramp.

PROF remains a commercial-stage business with negative earnings per share (EPS), so the path toward $11 depends less on near-term profit and more on sustained revenue growth from its TULSA-PRO prostate-ablation system and the newer Sonalleve product line. The company recently reported quarterly results that included a wider-than-expected loss, a reminder that revenue scaling and cost discipline remain the central questions for the investment case.

What Could Support a Move Toward the Target

  • Product adoption: TULSA-PRO offers an incision-free, MRI-guided alternative for prostate treatment, addressing a large and growing patient population.
  • Unanimous Buy consensus: All current analysts rate the stock a Buy, with targets well above the current price.
  • Revenue trajectory: The company is guiding toward meaningful top-line growth, and analysts see losses narrowing as sales scale.
  • Technical position: The stock trades above its 50-day and 200-day moving averages, reflecting improving momentum.

What Could Prevent the Target From Being Reached

  • Ongoing losses: The company is not yet profitable, and misses on EPS estimates can weigh on sentiment.
  • Competition: The prostate-treatment market includes established surgical and energy-based alternatives.
  • Valuation after a rally: Having rebounded sharply from $4.80, the stock could face profit-taking if growth disappoints.
  • Thin coverage: With few analysts following the name, price targets can be more volatile and less anchored than for larger companies.

Technical Levels and Market Structure

The most meaningful reference points are the 52-week low of $4.80 and the 52-week high of $8.95. The latter is the nearest clear resistance level and, if cleared, would put the stock at a multi-year high on the way toward the $10-to-$12 target zone. On the downside, the 50-day moving average near $6.30 and the 200-day moving average near $6.65 form nearby support, along with the psychological $6 level. The stock's ability to hold above these averages is an important signal for the durability of the recent uptrend.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state this explicitly. For PROF, the most important upcoming catalysts are quarterly earnings and revenue results, updates on TULSA-PRO commercial traction and reimbursement, and any changes to analyst estimates or targets. Given the company's reliance on revenue growth, investors should watch gross margins, cash burn, and commentary on new hospital accounts and procedure volumes rather than focusing solely on EPS, which is expected to remain negative in the near term.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Rather than relying on a single static price target, this approach helps traders spot changing trends, monitor existing positions, and discover new opportunities more efficiently. For investors tracking names like PROF, these signals can offer a timely, data-driven complement to traditional fundamental research.

Final Assessment

Whether PROF can reach $11 depends on its ability to sustain revenue growth while narrowing losses, and to hold investor confidence after a strong rally. The central target is an analyst-derived mean of $11, based on a tight $10-to-$12 range, implying a substantial move of roughly 48% from recent levels. The strongest supports are unanimous Buy ratings and an improving technical backdrop, while the principal obstacles are continued losses and the risk that a fast-rising stock consolidates before it can build on its gains. With earnings and commercial milestones still ahead, the target represents a genuine, analyst-grounded objective rather than a near-term certainty, and no outcome is guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

PROF and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PROF has been loosely correlated with OWLT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PROF jumps, then OWLT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROF
1D Price
Change %
PROF100%
-2.40%
OWLT - PROF
36%
Loosely correlated
+12.92%
MTD - PROF
28%
Poorly correlated
+1.42%
IART - PROF
28%
Poorly correlated
+2.29%
A - PROF
26%
Poorly correlated
+2.97%
NEOG - PROF
25%
Poorly correlated
+1.65%
More

Groups containing PROF

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PROF
1D Price
Change %
PROF100%
-2.40%
Medical/Nursing Services
industry (138 stocks)
-1%
Poorly correlated
-0.55%
Health Services
industry (238 stocks)
-1%
Poorly correlated
-1.51%
Can Profound Medical (PROF) Stock Reach $11?